MS
SBBP

Maven Securities’s Strongbridge Biopharma plc. SBBP Stock Holding History

Maven Securities’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-82,450
Closed -$173K – 936
2020
Q3 		$173K Buy
+82,450
New +$278K 0.01% 567

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Maven Securities's SBBP Position: Q4 2020 in Review

Maven Securities sold out of Strongbridge Biopharma plc. (SBBP) in Q4 2020, closing a stake of 82,450 shares — an estimated $173K sold.

Maven Securities first reported a position in SBBP in Q3 2020 and held it in 1 quarter. The position peaked at $173K in Q3 2020. 71 funds tracked by Wall St. Rank hold SBBP as of Q4 2020.

  • Maven Securities reported no remaining Strongbridge Biopharma plc. position as of Q4 2020 after selling out during the quarter.
  • Maven Securities sold 82,450 Strongbridge Biopharma plc. shares in Q4 2020, an estimated $173K.
  • Maven Securities first reported a position in Strongbridge Biopharma plc. in Q3 2020 and held it in 1 quarter.
  • Maven Securities's Strongbridge Biopharma plc. position peaked at $173K in Q3 2020.
  • 71 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q4 2020.

Based on Maven Securities's 13F filing for Q4 2020, filed 12 Feb 2021.